Legal Aspects of Biotechnology Innovation

Legal Aspects of Biotechnology Innovation

Legal Aspect of Biotechnology Innovation

The use of aspirin in: treating and preventing coronary artery disease; has been continually discussed as a safe way for effectively helping patients, who are suffering from the condition. Yet, the underlying amounts of dosages have been creating controversy among health care professionals, as a number of studies are confirming or denying the results of one another. In this study, researchers are seeking to determine the answer to the problem, by looking at various published and unpublished studies / clinical trials.

A Description of the Field of Invention and Background of Invention

Over the last several decades, aspirin has continued to create innovative solutions for dealing with a host of medical conditions. Where, it has been shown, as being an effective treatment against coronary artery disease. Yet, there is a lack of agreement about what is right amount of dosage that a patient needs to be taking. As the U.S. Food and Drug Administration sets the acceptable range for dosages between 50 mg / d to as high as 1,300 mg / d. (Campbell, 2007, pp. 2018 -- 2024) This is because the different studies that were conducted all provide a wide range of recommended quantities. The problem is: that with the different underlying levels of health in the individual; this guideline could prove to be in accurate. Where, it does not take into account, specific factors that could give the person to small or to large of a dosage. To rectify the situation the article Aspirin Dose for the Prevention of Cardiovascular Disease, examines these underlying effects by looking at various published and unpublished research trials. Once this is complete, it provides the greatest insights, as to how the underlying dosages should be determined.

Preparation of Claims

The different claims that are going to be examined, will determine the underlying effects of taking various dosages. Where, researchers are looking at numerous studies and information, to accurately decide the correct amount of aspirin an individual should be taking.

Types of Claims

Formulation or an Alternative Composition Claim

1. The alternate composition claim is: the long-term effects of various dosages on an individual. Where, researchers found that someone who is consistently prescribed amounts of aspirin between: 40 mg and 100 mg were able to dramatically slow platelets production. As the consistency of an aspirin regimen, would help to improve the body's ability to adjust to changes in lifestyle and diet. (Campbell, 2007, pp. 2018 -- 2024)

Method of Treatment Claim

The method of treating the different claims will be compared with: the different short, medium and long-term effects of specific facts; that could support or refute the statements of the author. (Campbell, 2007, pp. 2018 -- 2024)

Process of Manufacturing Claim

To determine the accuracy of the different claims made by the researchers, the article will look at 2,415 studies and references. The idea is to examine a variety of sources, to determine the full effects that various dosages will have on a number of individuals. (Campbell, 2007, pp. 2018 -- 2024)

Number of Claims

Independent Claims

1. The method of independent claim one wherein is: that dosages between 75 mg and 81 mg, will not have any kind of significant long-term impact on the individual.

2. The method of independent claim two wherein is: that 50% of respondents, who were given low dosages of aspirin, show little to no positive improvements in their condition.

3. The method of independent claim three wherein is: that women were more than likely, to see the positive effects from taking aspirin in comparison with men.

4. The method of the independent claim number four: is that the long-term effects of taking aspirin; will have a greater impact upon reducing the underlying levels of platelet formation in women. (Campbell, 2007, pp. 2018 -- 2024)

Dependent Claims

1. The method of claim number one wherein is: the use of aspirin therapy was first introduced by Paul Gibson in 1948. Yet, it was not until 30 years later that the benefits of taking aspirin were fully realized.

2. The method of claim number two wherein is: that LL Craven would build off of the ideas of Gibson in 1953, confirming some of the effects of using aspirin to treat coronary artery disease.

3. The method of claim number three wherein is: that there have been various studies all confirming the effectiveness of taking lower dosages of aspirin (with most recommending usage between 30mg and 130 mg).

4. The method of claim number four wherein: is that researchers found those who take dosages of 30 mg to 283 mg, saw a dramatic improvement in the underlying levels of health after a stroke.

5. The method of claim number five wherein: is that other studies have found similar effects as lower dosages, when patients are given greater amounts of aspirin (up to 1500 mg).

6. The method of claim number six wherein: is that 60 different research studies found no effect between changes in the underlying dosage.

7. The method of claim number seven wherein is: that aspirin taking through chewing or other means will help to increase the absorption rate.

8. The method of claim number eight wherein is: a large number of studies have provided, mixed results on the underlying effects of taking aspirin in treating coronary artery disease.

9. The method of claim number nine wherein is: that 60% of doctors believe that lower dosages of aspirin are more effective.

10. The method of claim number ten wherein is: that large clinical trials have not been able to show the effectiveness of using higher levels of dosage.

11. The method of claim number eleven wherein is: that those who have taken lower dosages after a stroke, will have a 14.7% chance of having a second one 2.6 years later, compared with 15.7% for higher dosages.

12. The method of claim number twelve wherein is: that 11 different studies showed similar rates of recurring stoke and heart attack (regardless of the dosage).

13. The method of claim number thirteen wherein is: that patients who received a dosage of 100 mg were able to see the best results from aspirin therapy.

14. The method of claim number fourteen wherein is: that aspirin taken without being chewed or by drinking water, can slow the effects by as much as 12 hours.

15. The method of claim number fifteen wherein is: that those individual who would take aspirin with water, would see the effects on the body within 15 minutes.

16. The method of claim number sixteen wherein is: that those individuals who took between 75 mg and 162 mg saw the same results 366 days later. (Campbell, 2007, pp. 2018 -- 2024)